| DN | Deiter's nucleus; dextrose-nitrogen; diabetic neuropathy; dibucaine number; dicrotic notch; dinitroc... |
|---|---|
| DNE | Director of Nursing Education; Doctor of Nursing Education |
| GNC | general nursing care; General Nursing Council; geriatric nurse clinician |
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
| NIC | National Informatics Center; neurogenic intermittent claudication; neurointensive care; nursing inte... |
| controlled thermonuclear research | General label for research on controlled thermonuclear fusion reactions. (09 Oct 1997) |
|---|---|
| health outcomes research | The measurement of the value of a particular course of therapy. Health outcomes research is based on the principle that every clinical intervention produces a change in the health status of a patient and that change can be measured. (12 Dec 1998) |
| health services research | The integration of epidemiologic, sociological, economic, and other analytic sciences in the study of health services. Health services research is usually concerned with relationships between need, demand, supply, use, and outcome of health services. The aim of the research is evaluation, particularly in terms of structure, process, output, and outcome. (12 Dec 1998) |
| dental research | The study of laws, theories, and hypotheses through a systematic examination of pertinent facts and their interpretation in the field of dentistry. (12 Dec 1998) |
| operations research | A group of techniques developed to apply scientific methods and tools to solve the problems of decision making in complex organizations and systems. Operations research searches for optimal solutions in situations of conflicting goals and makes use of mathematical models from which solutions for actual problems may be derived. (12 Dec 1998) |
| epidemiologic research design | The form and structure of analytic studies in epidemiologic and clinical research. (12 Dec 1998) |
| united states agency for health care policy and research | An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research. (12 Dec 1998) |
| united states office of research integrity | An office of the united states public health service organised in june 1992 to promote research integrity and investigate misconduct in research supported by the public health service. It consolidates the office of scientific integrity of the national institutes of health and the office of scientific integrity review in the office of the assistant secretary for health. The ori is in the office of the assistant secretary for health and its director reports directly to the assistant secretary for health, department of health and human services. (ri newsletter, 1993 jan; 1(1):1) (12 Dec 1998) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|